The Prognosis of “COVID-19 Pandemic and Obesity”: What We Learned from the Double Pandemic?

Abstract

The course of mortality and morbidity of COVID-19 disease is seen higher than expected. The presence of advanced age, male gender, obesity, hypertension, diabetes mellitus and chronic diseases were noteworthy in the COVID-19 pandemic, which occured in December 2019 worldwide. Obesity has been one of the considerable risk factors for mortality and morbidity for the patients with the clinical features of COVID-19 clinic. Here, the literature data in the COVID-19 pandemic regarding the role and the clinical value of obesity, adipose tissue and adipocytes in disease physiopathology, and the prognosis of pandemic and obesity are presented.

Keywords

• COVID-19
• PANDEMIC
• OBESITY
• PROGNOSIS

“COVID-19 Pandemisi ve Obezite” Prognozu: İki Pandemiden Ne Öğrendik?

Abstract

COVID-19 hastalığının mortalitesi ve morbiditesi beklenenden yüksek seyretmektedir. Dünya genelinde Aralık 2019’da başlayan COVID-19 pandemisinde hayatını kaybedenlerde ileri yaş, erkek cinsiyet, obezite, hipertansiyon, diabetes mellitus ve kronik hastalıkların varlığı dikkati çekmekteydi. Bilinen bir virüsün yaptığı pandemi, bilinmeyenlerle dolu bir hastalık tablosu olarak karşımıza çıkmıştır. Obezite, COVID-19’lu hastalarda mortalite ve morbidite açısından önemli risk faktörlerinden birisi olmuştur. Burada COVID-19 pandemisinde obezitenin yeri, klinik önemi, adipositler ve yağ dokusunun fizyopatolojiye katkısı, pandemi ve obezite prognozuna ait literatür verileri sunulmaktadır.

Keywords

• COVID-19
• PANDEMİ
• OBEZİTE
• PROGNOZ

References

1. 1-Becker, M.M. et al. Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc. Natl. Acad. Sci. USA 105, 19944–19949 (2008).
2. 2-Peiris, J.S., Guan, Y. & Yuen, K.Y. Severe acute respiratory syndrome. Nat. Med. 10, S88–S97 (2004)..
3. 3-Menachery VD, Yount BL Jr, Debbink K, et al. A SARS-like cluster of circulating bat coronaviruses shows potential for human emergence [published correction appears in Nat Med. 2016 Apr;22(4):446]. Nat Med. 2015;21(12):1508‐1513. doi:10.1038/nm.3985
4. 4- World Health Organization. WHO Director-General's opening remarks at the media briefing on COVID-19 - 11 March 2020. Available online at https://www.who.int/dg/speeches/detail/who-director-general-s-opening-remarks-at-the-media-briefing-on-COVID-19---11-march-2020, Accessed date: 20.05.2020.
5. 5-World Health Organization. Coronavirus disease (COVID-19) pandemic. Available online at https://www.who.int/emergencies/diseases/novel-coronavirus-2019 Accessed date: 11.06.2020.
6. 6- Maier HE, Lopez R, Sanchez N, et al. Obesity increases the duration of influenza A virus shedding in adults. J Infect Dis. 2018;218(9):1378‐1382. [PMC free article] [PubMed] [Google Scholar]).
7. 7-Neidich SD, Green WD, Rebeles J, et al. Increased risk of influenza among vaccinated adults who are obese. Int J Obes (Lond) 2017; 41:1324‐1330.
8. 8-Zumla A, Hui DS, Perlman S. Middle East respiratory syndrome. Lancet 2015; 386: 995–1007.

9. 9-Dietz W, Santos-Burgoa C. Obesity and its Implications for COVID-19 Mortality. Obesity (Silver Spring). 2020;28(6):1005. doi:10.1002/oby.22818.
10. 10-Samuels JD. Obesity and severe COVID-19 disease: a strong association [published online ahead of print, 2020 May 4]. Obesity (Silver Spring). 2020;10.1002/oby.22866. doi:10.1002/oby.22866.
11. 11-Kassir R. Risk of COVID-19 for patients with obesity. Obes Rev. 2020;21(6):e13034. doi:10.1111/obr.13034.
12. 12-9-Finer N, Garnett SP, Bruun JM. COVID-19 and obesity. Clin Obes. 2020;10(3):e12365. doi:10.1111/cob.12365.
13. 13-10-Hales K, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017‐2018. NCHS Data Brief, no. 360. Hyattsville, MD: National Center for Health Statistics; 2020.Google ScholarFull Text Article Linker
14. 14-Garg S, Kim L, Whitaker M, et al. Hospitalization rates and characteristics of patients hospitalized with laboratory-confirmed coronavirus disease 2019—COVID-NET, 14 states, March 1–30, 2020. MMWR Morb Mortal Wkly Rep. 2020;69:458-464. https://doi.org/10.15585/mmwr.mm6915e3
15. 15-Coronavirus Disease 2019 (COVID-19). Groups at Higher Risk for Severe Illness. Available at: https://www.cdc.gov/coronavirus/2019-ncov/need-extra-precautions/people-at-higher-risk.html. Last accessed: May 28, 2020.
16. 16- Ryan DH, Ravussin E, Heymsfield S. COVID 19 and the Patient with Obesity - The Editors Speak Out. Obesity (Silver Spring). 2020 Apr 1. doi: 10.1002/oby.2280
17. 17-ICNARC. Report on 196 patients critically ill with COVID-19., 20 March 2020, BMI distribution of patients critically ill with confirmed COVID-19, page 10. Available at https://www.icnarc.org/About/Latest-News/2020/03/22/Report-On-196-Patients-Critically-Ill-With-COVID-19 or https://www.icnarc.org/DataServices/Attachments/Download/96b455be-059e-ea11-9126-00505601089b, Accessed Date:28.05.2020.
18. 18-Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospitalization and critical illness among 4,103 patients with COVID-19 diseasein New York. medRxiv. 2020.04.08.20057794. https://doi.org/10. 1101/2020.04.08.20057794. Posted April 11, 2020. Accessed April19, 2020
19. 19-Uppot RN. Technical challenges of imaging & image-guided interventions in obese patients. Br J Radiol. 2018;91(1089):20170931. https://doi.org/10.1259/bjr.20170931.
20. 20-Gillespie T, Lane S. Moving the bariatric patient. Crit Care Nurs Q. 2018;41:297-301
21. 21-Acharya P, Upadhyay U, Qavi A, et al. The paradox prevails: outcomes are better in critically ill obese patients regardless of the comorbidity burden. J Crit Care. 2019;53:25-31.
22. 22- Richardson A, Chetboun M, Poissy J, et al. High prevalence of obesity in severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) requiring invasive mechanical ventilation. Obesity (Silver Spring). 2020.https://doi.org/10.1002/oby.22831.
23. 23-Zuo W, Zhao X, Chen YG. SARS coronavirus and lung fibrosis. In: Molecular Biology of the SARS-Coronavirus. Springer, Berlin, Heidelberg. 2010;247-258.
24. 24-Bhatraju PK, Ghassemieh BJ, Nichols M, et al. COVID-19 in Critically Ill Patients in the Seattle Region—Case Series. N Engl J Med 2020; doi: 10.1056/NEJMoa2004500.
25. 25-Naik PK, Moore BB. Viral infection and aging as cofactors for the development ofpulmonary fibrosis. Expert Rev Respir Med 2010;4,759-771.
26. 26. Tse GM, To KF, Chan PK, et al. Pulmonary pathological features in coronavirus associated severe acute respiratory syndrome (SARS). J Clin Pathol 2004;57,260-265.
27. 27. Habiel DM, Hogaboam CM. Heterogeneity of fibroblasts and myofibroblasts in pulmonary fibrosis. Curr Pathobiol Rep 2017;5,101-110.
28. 28. Wrapp D, Wang N, Corbett KS, et al. Cryo-EM structure of the 2019-nCoV spike in the prefusion conformation. Science 2020;367,1260-1263.
29. 29- Kruglikov IL. Interfacial Adipose Tissue in Systemic Sclerosis. Curr Rheumatol Rep. 2017;19(1):4. doi:10.1007/s11926-017-0627-y
30. 30- Kruglikov IL, Scherer PE. The role of adipocytes and adipocyte-like cells in the severity of COVID-19 infections [published online ahead of print, 2020 Apr 27]. Obesity (Silver Spring). 2020;10.1002/oby.22856. doi:10.1002/oby.22856.
31. 31-El Agha E, Moiseenko A, Kheirollahi V, et al. Two-way conversion between lipogenic and myogenic fibroblastic phenotypes marks the progression and resolution of lung fibrosis. Cell Stem Cell 2017;20,261-273 //
32. 32-Kökény G, Calvier L, Legchenko E, Chouvarine P, Mózes MM, Hansmann G. PPARγ is a gatekeeper for extracellular matrix and vascular cell homeostasis: beneficial role inpulmonary hypertension and renal/cardiac/pulmonary fibrosis. Curr Opin Nephrol Hypertens 2020;29,171-179.
33. 33-Marangoni RG, Masui Y, Fang F, et al. Adiponectin is an endogenous anti-fibrotic mediator and therapeutic target. Sci Rep 2017;7,1-12.
34. 34-Straub LG, Scherer PE. Metabolic messengers: adiponectin. Nat Metab 2019;1,334-339.
35. 35-Mendy A, Gopal R, Alcorn JF, Forno E. Reduced mortality from lower respiratory tract disease in adult diabetic patients treated with metformin. Respirology 2019;24,646-651.
36. 36- Malavazos AE, Corsi Romanelli MM, Bandera F, Iacobellis G. Targeting the Adipose Tissue in COVID-19 [published online ahead of print, 2020 Apr 21]. Obesity (Silver Spring). 2020;10.1002/oby.22844. doi:10.1002/oby.22844.
37. 37- Kheirollahi V, Wasnick RM, Biasin V, et al. Metformin induces lipogenic differentiation in myofibroblasts to reverse lung fibrosis. Nat Commun 2019;10,1-16.
38. 38-Johnson CA, Xie B, Liu C, et al. Socio-demographic and cultural comparison of overweight and obesity risk and prevalence in adolescents in Southern California and Wuhan, China. J Adolesc Health. 2006;39(6):e1–e8. doi: 10.1016/j.jadohealth.2006.07.011.
39. 39-TEMD Obezite, Lipid Metabolizması, Hipertansiyon Çalışma Grubu. Türkiye Endokrinoloji ve Metabolizma Derneği . Obezite Tanı ve Tedavi Kılavuzu. Bölüm 1.OBEZİTENİN ÖNEMİ, EPİDEMİYOLOJİK VERİLER ve PATOGENEZ, ISBN: 978-605-4011-31-5 8. Baskı: Nisan 2019 (Tıpkı basım);sayfa 12-14 http://temd.org.tr/admin/uploads/tbl_kilavuz/20190506163904-2019tbl_kilavuz5ccdcb9e5d.pdf Erişim Tarihi 25.05.2020.)
40. 40- Hales CM, Carroll MD, Fryar CD, Ogden CL. Prevalence of obesity and severe obesity among adults: United States, 2017–2018. NCHS Data Brief, no 360. Hyattsville, MD: National Center for Health Statistics. 2020. Available at https://www.cdc.gov/nchs/products/databriefs/db360.htm#Suggested_citation. Accessed 29.05.2020.
41. 41-Shi S, Qin M, Shen B, et al. Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China.JAMA Cardiol 2020; published online March 25. DOI:10.1001/jamacardio.2020.0950.
42. 42-Guo T, Fan Y, Chen M, et al. Cardiovascular implications of fatal outcomes of patients with coronavirus disease 2019 (COVID-19). JAMA Cardiol 2020; published online March 27. DOI:10.1001/jamacardio.2020.1017.
43. 43-Mehra MR, Desai SS, Kuy S, Henry TD, Patel AN. Cardiovascular Disease, Drug Therapy, and Mortality in COVID-19 [published online ahead of print, 2020 May 1]. N Engl J Med. 2020;NEJMoa2007621. doi:10.1056/NEJMoa2007621.
44. 44- Louie JK, Acosta M, Winter K, et al. Factors associated with death or hospital-ization due to pandemic 2009 influenza A(H1N1) infection in California. JAMA 2009;302:1896-1902.
45. 45-Perez LM, Pareja-Galeano H, Sanchis-Gomar F, Emanuele E, Lucia A, Galvez BG. 'Adipaging': ageing and obesity share biological hallmarks related to a dysfunctional adipose tissue. J Physiol. 2016;594:3187-3207.
46. 46-Hotchkiss RS, Karl IE. The pathophysiology and treatment of sepsis. N Engl J Med.2003;348(2):138-150.
47. 47- Zhou F, Yu T, Du R, et al. Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study. Lancet.2020;395(10229):1054-1062.
48. 48-Danzi GB, Loffi M, Galeazzi G, Gherbesi E. Acute pulmonary embolism and COVID-19 pneumonia: a random association?. Eur Heart J. 2020;41(19):1858. doi:10.1093/eurheartj/ehaa254
49. 49- Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost. 2020;18(5):1094‐1099. doi:10.1111/jth.14817
50. 50-Schmidt FM, Weschenfelder J, Sander C, et al. Inflammatory cytokines in general and central obesity and modulating effects of physical activity. PLoS One. 2015;10(3):e0121971.
51. 51-Caer C, Rouault C, Le Roy T, et al. Immune cell-derived cytokines contribute to obesityrelated inflammation, fibrogenesis and metabolic deregulation in human adipose tissue.Sci Rep. 2017;7(1):3000.
52. 52- Varga Z, Flammer AJ, Steiger P, et al. Endothelial cell infection and endotheliitis in COVID-19. Lancet. 2020;395(10234):1417‐1418. doi:10.1016/S0140-6736(20)30937-5.
53. 53-Garofalo C, Borrelli S, Minutolo R, Chiodini P, De Nicola L, Conte G. A systematic review and meta-analysis suggests obesity predicts onset of chronic kidney disease in the general population. Kidney Int. 2017;91(5):1224‐1235. doi:10.1016/j.kint.2016.12.013
54. 54-Abuissa H, Jones PG, Marso SP, O'Keefe JH Jr. Angiotensin-converting enzyme inhibitors or angiotensin receptor blockers for prevention of type 2 diabetes: a meta-analysis of randomized clinical trials. J Am Coll Cardiol. 2005;46(5):821‐826. doi:10.1016/j.jacc.2005.05.051.
55. 55- Sanchis-Gomar F, Lavie CJ, Perez-Quilis C, Henry BM, Lippi G. Angiotensin-Converting Enzyme 2 and Antihypertensives (Angiotensin Receptor Blockers and Angiotensin-Converting Enzyme Inhibitors) in Coronavirus Disease 2019. Mayo Clin Proc. 2020;95(6):1222‐1230. doi:10.1016/j.mayocp.2020.03.026
56. 56- Wu J, Li W, Shi X, et al. Early antiviral treatment contributes to alleviate the severity and improve the prognosis of patients with novel coronavirus disease (COVID-19) [published online ahead of print, 2020 Mar 27]. J Intern Med. 2020;10.1111/joim.13063. doi:10.1111/joim.13063.
57. 57- Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-CoV-2 Admitted to ICUs of the Lombardy Region, Italy [published online ahead of print, 2020 Apr 6]. JAMA. 2020;323(16):1574‐1581. doi:10.1001/jama.2020.5394
58. 58- Stefan, N., Schick, F. & Häring, H. U. Causes, characteristics, and consequences of metabolically unhealthy normal weight in humans. Cell Metab. 2017;26:292–300.
59. 59- Bornstein, S.R., Dalan, R., Hopkins, D. et al. Endocrine and metabolic link to coronavirus infection. Nat Rev Endocrinol 16, 297–298 (2020). https://doi.org/10.1038/s41574-020-0353-9
60. 60- Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China [published online ahead of print, 2020 May 14]. Diabetes Care. 2020;dc200576. doi:10.2337/dc20-0576
61. 61-Cai Q, Chen F, Wang T, et al. Obesity and COVID-19 Severity in a Designated Hospital in Shenzhen, China [published online ahead of print, 2020 May 14]. Diabetes Care. 2020;dc200576. doi:10.2337/dc20-0576
62. 62- Peng YD, Meng K, Guan HQ, et al. Zhonghua Xin Xue Guan Bing Za Zhi. 2020;48(0):E004. doi:10.3760/cma.j.cn112148-20200220-00105.
63. 63- Kalligeros M, Shehadeh F, Mylona EK, et al. Association of Obesity with Disease Severity among Patients with COVID-19 [published online ahead of print, 2020 Apr 30]. Obesity (Silver Spring). 2020;10.1002/oby.22859. doi:10.1002/oby.22859
64. 64- Richardson S, Hirsch JS, Narasimhan M, et al. Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area [published online ahead of print, 2020 Apr 22] [published correction appears in doi: 10.1001/jama.2020.7681]. JAMA. 2020;323(20):2052‐2059. doi:10.1001/jama.2020.6775
65. 65- Goyal P, Choi JJ, Pinheiro LC, et al. Clinical Characteristics of Covid-19 in New York City. N Engl J Med. 2020;382(24):2372‐2374. doi:10.1056/NEJMc2010419
66. 66- Lighter J, Phillips M, Hochman S, et al. Obesity in patients younger than 60 years is a risk factor for Covid-19 hospital admission [published online ahead of print, 2020 Apr 9]. Clin Infect Dis. 2020;ciaa415. doi:10.1093/cid/ciaa415
67. 67- Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ. 2020;369:m1985. Published 2020 May 22. doi:10.1136/bmj.m1985.
68. 68-Chiappetta S, Sharma AM, Bottino V, Stier C. COVID-19 and the role of chronic inflammation in patients with obesity [published online ahead of print, 2020 May 14]. Int J Obes (Lond). 2020;1‐3. doi:10.1038/s41366-020-0597-4.
69. 69-Sanchis-Gomar F, Lavie CJ, Mehra MR, Henry BM, Lippi G. Obesity and outcomes in COVID-19: when an epidemic and pandemic collide. Mayo Clin Proc 2020; published online May 19. DOI:10.1016/j.mayocp.2020.05.006.
70. 70-James WP. WHO recognition of the global obesity epidemic. Int J Obes (Lond). 2008;32 Suppl 7:S120‐S126. doi:10.1038/ijo.2008.247
71. 71-Report of a WHO consultation. Obesity: preventing and managing the global epidemic. World Health Organ Tech Rep Ser. 2000;894:i‐253.
72. 72-Roth J, Qiang X, Marbán SL, Redelt H, Lowell BC. The obesity pandemic: where have we been and where are we going?. Obes Res. 2004;12 Suppl 2:88S‐101S. doi:10.1038/oby.2004.273.
73. 73-Mitchell NS, Catenacci VA, Wyatt HR, et al. Obesity: overview of an epidemic. Psychiatr Clin North Am. 2011;34(4):717–32.
74. 74- Yeo C, Ahmed S, Oo AM, Koura A, Sanghvi K, Yeo D. COVID-19 and Obesity-the Management of Pre- and Post-bariatric Patients Amidst the COVID-19 Pandemic [published online ahead of print, 2020 May 9]. Obes Surg. 2020;1‐3. doi:10.1007/s11695-020-04670-6.
75. 75-Bhasker AG, Greve JW. Are Patients Suffering from Severe Obesity Getting a Raw Deal During COVID-19 Pandemic? [published online ahead of print, 2020 May 12]. Obes Surg. 2020;1‐2. doi:10.1007/s11695-020-04677-z.